The reproducibility of PD-L1 scoring in lung cancer: can the pathologists do better?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed.

1. Impact of vitamin D plasma levels on in vitro natural killer cell cytotoxicity against non-small cell lung carcinoma in the presence of nivolumab.Internal and emergency medicine · 2026
   Article
2. Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8JCO precision oncology · 2025
   Article
3. PD-L1 Scoring Models for Non-Small Cell Lung Cancer in China: Current Status, AI-Assisted Solutions and Future Perspectives.Thoracic cancer · 2025
   Review
4. Current Biomarkers in Non-Small Cell Lung Cancer-The Molecular Pathologist's Perspective.Diagnostics (Basel, Switzerland) · 2025
   Review
5. Companion diagnostic requirements for spatial biology using multiplex immunofluorescence and multispectral imaging.Frontiers in molecular biosciences · 2023
   Review
6. Artificial intelligence-assisted system for precision diagnosis of PD-L1 expression in non-small cell lung cancer.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022
   Article
7. Cancer Immunotherapy with Immune Checkpoint Inhibitors-Biomarkers of Response and Toxicity; Current Limitations and Future Promise.Diagnostics (Basel, Switzerland) · 2022
   Review
8. Multiplex Immunofluorescence and Multispectral Imaging: Forming the Basis of a Clinical Test Platform for Immuno-Oncology.Frontiers in molecular biosciences · 2021
   Review
9. Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 Expression.Head and neck pathology · 2020
   Article
10. Age and sex have no impact on expression levels of markers of immune cell infiltration and immune checkpoint pathways in patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy.Cancer immunology, immunotherapy : CII · 2019
    Article
11. Precision immunoprofiling by image analysis and artificial intelligence.Virchows Archiv : an international journal of pathology · 2019
    Review
12. Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression.Journal of Cancer · 2019
    Article
13. A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging.Cell · 2018
    Article
14. Correlation Between ImageJ and Conventional Manual Scoring Methods for Programmed Death-Ligand 1 Immuno-Histochemically Stained Sections.Technology in cancer research & treatment
    Article

Corrections and comments

• Comment on
  Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung Cancer.2017

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.